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INTRODUCTION
Atopic dermatitis (AD) is a persistent, chronically relapsing 
inflammatory skin disease in which abnormal hematopoietic 
cells circulate and infiltrate skin and respiratory tissue at sites 
perturbed by irritants, antigens, and infectious agents. AD is as-
sociated with multiple immunological abnormalities, and 80% 
of patients suffer from defective regulation of IgE production.
1 
AD can range from mild, localized lesions to generalized ec-
zematous lesions. Although a number of patients with AD re-
spond to topical therapy, others have severe resistant disease 
which is not controlled with first- or second-line topical thera-
pies. Therefore, AD may be considered as a systemic disease for 
which there are no satisfactory systemic therapies, although 
topically applied medications, including corticosteroid and cy-
closporine agents, give relief in some patients.
2-4 Long-term, 
chronic application of topical steroids may supplant the need 
for systemic therapy in many cases. Newer therapies such as ta-
crolimus are effective, but are limited to second-line therapy af-
ter initial treatments have failed. Oral cyclosporine has also been 
shown to be effective; however, its use is limited by adverse ef-
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fects such as renal toxicity. Approximately 20% of patients dis-
continue cyclosporine treatment within 2 years because of ad-
verse effects.
5,6
Intravenous immunoglobulin (IVIg) is prepared by cold etha-
nol fractionation of pooled plasma, followed by additional viral 
inactivation procedures. The final product is a pure concentrate 
of IgG (with small amounts of IgA and IgM) with intact function 
and minimal impurities.
7,8 The immunomodulatory mechanism 
of IVIg is thought to be mediated by interactions of the Fc por-
tion of IgG with Fc receptors and complement, interactions of 
the antigen-binding variable region F(ab)2, or substances other 
than antibodies in IVIg preparations.
9 Previous research has 
shown that IVIg significantly modulates the production of sev-
eral cytokines, including interleukin (IL)-1, IL-2, IL-3, IL-4, IL-5, 
IL-10, tumor necrosis factor-α, and granulocyte-macrophage 
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Purpose:  The present study investigates the long-term effects of intravenous immunoglobulin (IVIg) therapy for the treatment of moderate to se-
vere childhood atopic dermatitis (AD). Previous research indicates that IVIg can treat severe AD; however, the effectiveness of IVIg has not been 
confirmed in prospective, blinded clinical trials.  Methods:  Forty eligible children with moderate to severe AD, as defined by the criteria of Hanifin 
and Rajka, were enrolled in a randomized, placebo-controlled study. After the completion of an initial screening visit (V0), the patients were random-
ly allocated into therapy (n=30) and control (n=10) groups (V1). Thirty children were each treated with three injections of 2.0 g/kg IVIg at 1-month 
intervals over a 12-week period. Ten children were treated with placebo. Assessments were conducted after each injection (V2, V3, and V4) and at 3 
(V5) and 6 months (V6) after completed treatment.  Results:  The disease severity index was significantly decreased at V5 compared with the value 
at V1 (P<0.05). There were no significant changes in the total IgE level or total eosinophil count in peripheral blood at the last injection (V4) compared 
with the value at V1. The interleukin (IL)-5/interferon (IFN)-γ ratio was assessed in T-helper 1 (Th1) and Th2 cells. The ratio significantly decreased be-
tween V1 and V5, after which it increased, such that the ratio at V6 was not significantly different from that at V1. Compared with the level at V1, the 
intercellular cell adhesion molecule-1 level at V4 did not differ significantly, but the level at V5 was lower.  Conclusions:  This study suggests that 
IVIg therapy may clinically improve AD in patients after 3 months of therapy, but the improvement may decline by 6 months after therapy.
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colony-stimulating factor, as well as cytokine antagonists (IL-1 
receptor antagonist), by monocyte-macrophages and lympho-
cytes.
10 It appears that the biological anti-inflammatory effects 
of IVIg involve the participation of both the F(ab)2 and Fc regions 
in the formation of an IgG-antigen complex. These regions are 
associated with the inhibition of lymphocyte proliferative re-
sponses and the modulation of T-helper 1 (Th1) and Th2 cyto-
kine production. This effect of IVIg is mediated by the inhibi-
tion of differentiation and maturation of dendritic cells (DCs) in 
vitro, with down-regulated expression of co-stimulatory mole-
cules, thereby impairing the ability of mature DCs to produce 
IL-12 and enhancing their ability to produce IL-10. The conse-
quences are the inhibition of autoreactive and alloreactive T-
cell activation and proliferation.
11,12
IVIg therapy has consistently demonstrated activity in patients 
with AD, including severe AD,
13 although its effectiveness has 
not been confirmed in prospective, blinded clinical trials. Pa-
tients with Kawasaki disease or idiopathic thrombocytopenic 
purpura and concomitant AD who received IVIg showed im-
provement of their dermatitis.
14,15 One study gave mixed results, 
with the best response occurring in patients with extremely high 
IgE levels.
16 Reports on severe childhood AD suggest that IVIg 
can lead to improved symptoms when used as a monotherapy; 
nine out of 10 children improved when given 2 g/kg IVIg.
17 How-
ever, most published research has evaluated only the short-term 
effects of IVIg.
The present study was conducted to assess the long-term ef-
fects of IVIg therapy in moderate to severe childhood AD.
MATERIALS AND METHODS
Patients
Forty eligible children with moderate to severe AD, as defined 
by the criteria of Hanifin and Rajka
18, were enrolled in a ran-
domized, placebo-controlled study after an initial screening 
visit (V0) (Fig. 1). Eligibility criteria included AD present on 
more than 30% of the body surface, no response to convention-
al therapy, and age older than 2 years. Informed consent was 
obtained from either the child or a parent. Allergy skin prick tests 
or in vitro allergy tests (Unicap: Phardia, Uppsala, Sweden) were 
conducted at the screening visit (V0). The patients were random-
ized at the next clinic visit (V1) (Fig. 1). Patients were allowed to 
use only steroid-free hydrophilic or emollient ointment on the 
skin as adjunctive therapy. Seven patients did not complete the 
study: five IVIg subjects suffered side effects, including head-
ache, nausea, and abdominal pain, and two control subjects 
did not complete the trial for personal reasons. This study was 
approved by the Korean FDA (IVIg IIT Atopy-No. 48) and the 
Hanyang University Guri Hospital IRB committee.
Methods
The IVIg patients received an injection of IVIg (Greencross 
Pharm Co, Seoul, Korea) at 2.0 g/kg body weight/month at each 
monthly visit (V2, V3, and V4) for 12 weeks (Fig. 1). The patients 
were also assessed at each clinic visit and at 3 (V5) and 6 months 
(V6) after the final injection. Patients with headache or nausea 
were permitted to take oral acetaminophen. Placebo group re-
ceived general topical moisturizing lotion, 1% hydrocortisone 
cream and took oral antihistamines if they complaint itching 
for controlling itching skin as same to IVIg group. At V1, V4, V5, 
and V6, laboratory tests were performed for blood chemistry, 
total IgE, eosinophil cationic protein (ECP), IL-5, interferon 
(IFN)-γ, and intercellular cell adhesion molecule (ICAM)-1. 
Disease severity was assessed by the criteria of Hanifin and Raj-
ka
18, and included clinical severity and total body surface area 
(TBSA). Disease severity was assessed with the SCORAD index, 
which was calculated as A/5+7×B/2+C, where A is the TBSA 
measured as a percentage of lesional skin according to the rule 
of nines; B is the clinical severity consisting of six parameters: 
erythema, edema/papulation, excoriation, oozing/vesicle, li-
chenification, and dryness with pigmentation/depigmentation; 
and C is a subjective measurement of symptoms such as pruri-
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Fig. 1.  Study design of intravenous immunoglobulin (IVIg) therapy, blood specimen collection for laboratory analyses, and evaluation of clinical efficacy.
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tus and loss of sleep. Parameters A and B were scaled from 0 to 
3; parameter C, from 0 to 10. To minimize potential variation, 
the same physician measured the disease severity at each visit 
(Table 1).
Determination of cytokine concentrations
The concentrations of IL-5, IFN-γ, and ICAM-1 were deter-
mined by cytometric bead array assays (Bio-Plex; Bio-Rad Lab-
oratories, Hercules, CA, USA) according to the manufacturer’s 
protocol. All measurements were made in duplicate, with <10% 
variation between the two measurements.
Statistical analysis
The characteristics of the IVIg and placebo groups at V0 were 
compared using the Mann-Whitney U test. Disease severity 
was compared between the groups at baseline (V1) and at V2, 
V3, V4, V5, and V6. Differences between visits were analyzed by 
multiple comparisons as ANOVA. Analyses were performed us-
ing the SPSS statistical package, version 11.5 (SPSS Inc., Chica-
go, IL, USA). A value of P<0.05 was taken to indicate statistical 
significance.
RESULTS
Clinical effects of IVIg therapy in children with moderate to 
severe AD
Fig. 2 presents the mean percentage improvements of clinical 
parameters at each visit. The SCORAD index declined until 3 
months after the last IVIg injection (V5) and did not change sig-
nificantly during the subsequent 3 months (V6) (V1: 61.5±13.0, 
V4: 46.9±17.3, V5: 32.1±19.4, and V6: 39.3±18.4; V1 vs. V5: 
P<0.05) (Fig. 2, Table 2). The TBSA parameter of the SCORAD 
index improved until V5, but declined by V6 (V1: 50.5±12.8, 
V4: 40.7±11.9, V5: 29.7±14.2, and V6: 36.8±13.7; V1 vs. V5: 
P<0.05) (Fig. 3A). The scores for subjective symptoms such as 
itching and loss of sleep did not change significantly during the 
Table 1.  Subjective characteristics in study
Group IVIg Placebo Total P value 
No. of patients 30 10 40
Age (yr) 6.3±3.4 6.5±5.7 6.4±4.1
Sex (No.)
Male 18 4 22
Female 12 6 18
SCORAD index 61.5±13.3 42.1±9.9 55.9±15.1 >0.05
Total IgE level (IU/mL) 571.2±769.6 803.9±1134.0 692.8±922.6 >0.05
Eosinophil count (/mm
3) 529.4±472.2 290.0±179.2 461.0±421.8 >0.05
IVIg, intravenous immunoglobulin.
Table 2.  Comparison of SCORAD index, serum IgE, and eosinophil count between children with IVIg treatment and the controls
Visit 
SCORAD index Serum IgE (IU/mL) Eosinophil count (/mm
3)
IVIg Control IVIg Control IVIg Control
V1  61.5±13.0*  42.1±9.9  571.2±753.4  615.2±1023.2  529.4±462.6  290±179.3 
V4  46.9±17.3*  40.4±6.3  384.9±519.5  598.8±858.4  397.6±342.8  247.1±153.1 
V5  32.1±19.4*  35.7±8.9  493.9±620.3  622.0±932.5  470.8±411.7  330±150.5 
V6  39.3±18.4  35.9±9.6  548.9±677.2  633.9±946.7  547.6±393.3  270.0±71.3 
*There shows significantly differences of SCORAD between IVIg and control at V1 vs. V4 (P=0.005) and V1 vs. V5 (P=0.17).
IVIg, intravenous immunoglobulin; V1, before therapy; V4, during therapy; V5, 3-month follow-up visit; V6, 6-month follow-up visit.
Fig. 2.  SCORAD index before (V1) and during therapy (V4), and at 3 (V5) and 6 
months (V6) after the last intravenous immunoglobulin (IVIg) injection. The SCO-
RAD index was significantly lower at the 3-month follow-up visit (V5) compared 
with the index at V1, but it had increased by the 6-month follow-up visit (V6).
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study (V1: 14.1±2.0, V4: 12.0±2.9, V5: 10.2±3.6, and V6: 12.0±
3.2) (Fig. 3B). The SCORAD index of the control group did not 
improve significantly until V6.
Immunological parameters in peripheral blood
The total serum IgE concentration was initially elevated in all 
subjects (V0). The levels declined during IVIg treatment, were 
higher at the 3-month post-treatment visit (V5), and returned 
to initial levels by 6 months after treatment (V1: 571.2±753.4, 
V4: 384.9±519.5, V5: 493.9±620.3, and V6: 548.9±677.2 IU/mL) 
(Fig. 4A, Table 2). The total eosinophil count in peripheral blood 
demonstrated a similar pattern: it decreased during IVIg treat-
ment, but returned to the initial level by 6 months post-treat-
ment (V1: 529.4±462.6, V4: 397.6±342.8, V5: 470.8±411.7, V6: 
547.6±393.3 per mm
2) (Fig. 4B, Table 2). The ECP level was also 
decreased at 3 months post-treatment, but returned to the ini-
tial level by 6 months post-treatment (V1: 91.7±49.5, V4: 62.1±
30.5, V5: 58.1.2±57.9, V6: 94.8±41.6 μg/L) (Fig. 5).
Changes in IL-5, INF-γ, and ICAM-1 levels with IVIg treatment
The IL-5 concentration decreased between V1 and V4, but the 
difference was not statistically significant. Between V1 and V5, 
the IL-5 level decreased significantly (P<0.05). By 6 months 
post-treatment, the IL-5 level had returned to the initial con-
centration (V1: 89.2±34.8, V4: 73.3±36.7, V5: 64.3±37.9, and 
V6: 80.1±30.7 pg/mL; V1 vs. V5: P<0.05) (Fig. 6A). The IFN-γ 
Fig. 3.  Total body surface area of lesions (A) and subjective symptoms score (B) before (V1) and during therapy (V4), and at 3 (V5) and 6 months (V6) after the last 
IVIg injection. The total body surface area of lesions was significantly lower at the 3-month follow-up visit (V5) compared with the area at V1, but it had increased by 
the 6-month follow-up visit (V6). The subjective symptoms score did not change significantly.
S
u
b
j
e
c
t
i
v
e
 
s
y
m
p
t
o
m
 
s
c
o
r
e
 
  20
15
10
5
0
  V1  V4  V5  V6
T
o
t
a
l
 
b
o
d
y
 
s
u
r
f
a
c
e
 
a
r
e
a
 
(
%
) 80
70
60
50
40
30
20
10
0
  V1  V4  V5  V6
P<0.05
A B
A B
S
e
r
u
m
 
I
g
E
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
I
U
/
m
L
) 3,000
2,500
2,000
1,500
1,000
500
0
  V1  V4  V5  V6
T
o
t
a
l
 
e
o
s
i
n
o
p
h
i
l
 
c
o
u
n
t
 
(
/
m
m
3
)
2,500
2,000
1,500
1,000
500
0
  V1  V4  V5  V6
Fig. 4.  The serum IgE concentration (A) and total eosinophil count (B) before (V1) and during therapy (V4), and at 3 (V5) and 6 months (V6) after the last IVIg injection. 
These parameters did not change significantly.
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Fig. 5.  Eosinophil cationic protein (ECP) concentration before (V1) and during 
therapy (V4), and at 3 (V5) and 6 months (V6) after the last IVIg injection. The 
ECP concentration was significantly lower (P < 0.05) at the 3-month follow-up 
visit (V5) compared with the concentration at V1, but it had increased signifi-
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concentration was higher at V4 and V5 compared with that at 
V1 and decreased by V6, although the differences were not sig-
nificant (V1: 143.7±51.2 pg/mL, V4: 195.0±98.6 pg/mL, V5: 
194.0±85.6 pg/mL, and V6: 171.2±68.8 pg/mL) (Fig. 6B). The 
IL-5/IFN-γ ratio, assessed for Th1 and Th2, was significantly 
lower at V4 and V5 compared with that at V1 and increased by 
V6 (V1: 0.67±0.28, V4: 0.45±0.30, V5: 0.39±0.27, and V6: 0.51±
0.23; V1 vs. V4, and V1 vs. V5: P<0.05) (Fig. 7). The concentra-
tion of ICAM-1 was lower at V4 than at V1, but not significantly 
lower. The ICAM-1 concentration decreased significantly be-
tween V1 and V5 (P<0.05), but was higher at V6, approaching 
the level at V1 (V1: 112.2±28.2, V4: 99.4±16.1, V5: 61.3±36.9, 
and V6: 94.9±31.8 pg/mL) (Fig. 8).
Safety of IVIg treatment
Of the 30 children initially treated with IVIg, five discontinued 
therapy because of side effects: four due to severe headache and 
nausea after the first (V2) and second (V3) IVIg injections, and 
the fifth due to low-grade fever, headache, and vomiting after 
the first IVIg injection. These side effects were transient and 
self-limiting, and arose during the first few hours after injection.
DISCUSSION
The results of this long-term study demonstrate that the clini-
cal severity of AD showed improvement for 3 months (V5) after 
the last IVIg injection, but the improvement had declined by 6 
months post-treatment (V6). Total serum IgE and eosinophil 
Fig. 6.  The IL-5 (A) and IFN-γ (B) concentrations before (V1) and during therapy (V4), and at 3 (V5) and 6 months (V6) after the last intravenous immunoglobulin (IVIg) 
injection. The IL-5 level was significantly lower (P<0.05) at the 3-month follow-up visit (V5) compared with the level at V1, but it had increased by the 6-month fol-
low-up visit (V6). The IFN-γ level did not change significantly.
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Fig. 7.  The IL-5/IFN-γ ratio before (V1) and during therapy (V4), and at 3 (V5) 
and 6 months (V6) after the last intravenous immunoglobulin (IVIg) injection. 
The IL-5/IFN-γ ratio was significantly lower at the 3-month follow-up visit (V5) 
compared with the ratio at V1, but it had increased by the 6-month follow-up 
visit (V6).
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tion. The ICAM-1 concentration was significantly lower at the 3-month follow-
up visit (V5) compared with the concentration at V1, but it had increased by the 
6-month follow-up visit (V6).Jee et al.
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count decreased during therapy and for 3 months post-treat-
ment (V5), but had returned to initial levels after another 3 
months (V6). Similarly, immunological parameters, including 
the levels of ECP, IL-5, and ICAM-1, in peripheral blood de-
creased until 3 months post-treatment (V5), but had increased 
by the 6-month follow-up visit (V6). The level of IFN-γ in-
creased until 3 months after treatment, but decreased over the 
subsequent 3 months.
Cumulative toxicity and the lack of efficacy may limit systemic 
glucocorticoid use, and patients severely affected by AD often 
require immunosuppressive treatment, including IFN-γ, cyclo-
sporine, and IVIg. Patients with Kawasaki disease or idiopathic 
thrombocytopenic purpura with concomitant AD who received 
IVIg showed improvement of the dermatitis.
14 In that study, four 
patients with AD had marked improvement of dermatitis symp-
toms after one dose of IVIg therapy (400 mg/kg infused for 5 
days), with significant improvement on days 4–7 after treatment. 
Two patients with idiopathic thrombocytopenic purpura en-
tered remission for AD and did not require further treatment. 
However, an open label study of IVIg in patients with severe AD 
or hyper-IgE syndrome showed no clinical improvement,
16 and 
a randomized prospective study of IVIg in adults with severe 
AD failed to show a significant clinical effect.
17 Therefore, the use 
of IVIg in the treatment of AD remains controversial. To date, 
only a few individuals (10 children and 30 adults) have been 
treated with IVIg, and those studies were relatively short, with 
durations and response times of less than 3 months.
The current study included 30 eligible children who were treat-
ed with high-dose IVIg for 12 weeks and 10 children who were 
treated with placebo. The subjects were administered monthly 
injections of IVIg (2.0 g/kg body weight/month) over a 12-week 
period. Assessment was conducted after each treatment and at 
3 and 6 months after treatment; thus, the final assessment was 
at 9 months after the start of the study. The improvements in 
AD, assessed based on clinical severity and immunological pa-
rameters such as ECP, lasted for 3 months after the last IVIg 
treatment. However, at the long-term follow-up at 6 months 
post-treatment, both the clinical and immunological improve-
ments showed a trend back to the initial status.
Preparations of IVIg consist of intact IgE molecules with a dis-
tribution of IG subclasses corresponding to that in normal se-
rum. Subclass distribution varies among preparations, and some 
products have lower physiological levels of IgG3 and/or IgG4. 
IVIg contains small amounts of other proteins and products, 
such as albumin, IgA, IgE, IgM, sugars, and salts. The monomer 
and dimer contents also vary among preparations and include 
up to 3% non-active polymers.
19 These proteins and other mol-
ecules may affect the tolerability and half-life of IVIg infusions. 
Generally, the half-life of injected IVIg is approximately 2-3 
weeks, but this varies depending on the immune status of the 
patient. The present study demonstrated that IVIg therapy (2.0 
g/kg/month for 3 months) showed efficacy at 3 months, but not 
6 months, after the final injection.
Previous studies have reported elevated serum levels of solu-
ble ICAM-1 and endothelial leukocyte adhesion molecule 
(ELAM)-1 in patients with severe atopic eczema. Moreover, E-
selectin and VCAM-1 are critical adhesion molecules for the 
trafficking of memory T cells and eosinophils into skin lesions 
of AD.
20-22 Serum levels of the intracellular adhesion molecules 
ICAM-1 and ECP in previous studies correlated with improve-
ments in AD; therefore, we measured ICAM-1 and ECP as mark-
ers for efficacy of IVIg in the present study. IVIg reduced the lev-
els of ICAM-1 and ECP until 3 months after the final IVIg treat-
ment. The decreased levels of ICAM-1 and ECP suggest that IVIg 
therapy may decrease the influx of inflammatory cells such as 
eosinophils in skin lesions.
It has been proposed that Th2 cells play a key pathogenic role 
in AD through regulatory T-cell modulation. There is further ev-
idence that monocytes from AD patients secrete increased 
amounts of the Th2 cytokines IL-4, IL-5, IL-10, and IL-13. A 
number of studies have indicated that the immunological bal-
ance shifts toward a Th2 response in AD,
23,24 while several other 
reports have suggested that Th1, rather than Th2, cells are im-
portant for AD pathogenesis. One study found high levels of 
IFN-γ mRNA and protein expression in 80% of the eczematous 
skin of AD patients.
25 Further research has suggested that acute 
inflammation is mediated by Th2 cell cytokines, whereas 
chronic lesions had an increased number of cells expressing IL-
12 mRNA compared with unaffected skin.
26 However, these cells 
were limited to the skin lesion and were not found in the periph-
eral blood. In the present study, the IL-5 level was significantly 
decreased at 3 months post-treatment treatment, but the IFN-γ 
level did not change significantly during or after treatment. These 
findings suggest that IVIg therapy may not influence T-cells, but 
that Th1 cells become more dominant. The apparent switch 
from Th2 to Th1 dominance may explain the clinical improve-
ment at 3 months after IVIg therapy and its absence 3 months 
later, although this requires further investigation.
There were a few minor side effects associated with IVIg infu-
sion in the present study, but most were self-limiting and oc-
curred only during the first few hours after infusion. The side 
effects may be reduced by slowing the rate of infusion or ad-
ministering NSAIDs or acetaminophen prior to the next IVIg 
infusion. Side effects such as headache and nausea might have 
resulted from the high dose of IVIg or might have been a conse-
quence of a low level of IgG aggregation, immune complex for-
mation, or complement activation in the IVIg preparationt.
27,28
It is important to consider the balance between pharmacolog-
ical efficacy and drug cost with respect to time commitment 
and financial implications of this therapy. The present study 
suggests that patients may need to receive IVIg therapy every 6 
months, and this cost should be compared with the estimated 
improvement in the quality of life. Therefore, IVIg therapy should 
not be introduced until after the physician and patient have Effect of IVIg in Atopic Dermatitis in Childhood AAIR 
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considered both the clinical efficacy and the cost of the thera-
py.
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